Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs

S. Allstadt Frazier, D. S. Mckemie, T. A. Guerrero, H. Lachapelle, Katherine A Skorupski, Philip H Kass, C. O. Rodriguez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m2 to seven dogs. Carboplatin was administered at 240-300 mg/m2 in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose-limiting toxicity was hepatic at a dose of 8 mg/m2. Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ-glutamyltranspeptidase values were noted.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalVeterinary and Comparative Oncology
Volume12
Issue number1
DOIs
StatePublished - Mar 2014

Fingerprint

rosiglitazone
Clinical Trials, Phase I
Carboplatin
clinical trials
mouth
Dogs
neoplasms
dogs
toxicity
Neoplasms
dosage
hypoglycemic agents
Maximum Tolerated Dose
PPAR gamma
bilirubin
Alanine Transaminase
alanine transaminase
Bilirubin
Hypoglycemic Agents
blood glucose

Keywords

  • Canine
  • Carboplatin
  • Chemotherapy
  • Comparative oncology
  • Oncology
  • Rosiglitazone
  • Toxicity

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs. / Allstadt Frazier, S.; Mckemie, D. S.; Guerrero, T. A.; Lachapelle, H.; Skorupski, Katherine A; Kass, Philip H; Rodriguez, C. O.

In: Veterinary and Comparative Oncology, Vol. 12, No. 1, 03.2014, p. 1-9.

Research output: Contribution to journalArticle

Allstadt Frazier, S. ; Mckemie, D. S. ; Guerrero, T. A. ; Lachapelle, H. ; Skorupski, Katherine A ; Kass, Philip H ; Rodriguez, C. O. / Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs. In: Veterinary and Comparative Oncology. 2014 ; Vol. 12, No. 1. pp. 1-9.
@article{f9eb10f91f8642d297cde33901d6325f,
title = "Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs",
abstract = "Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m2 to seven dogs. Carboplatin was administered at 240-300 mg/m2 in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose-limiting toxicity was hepatic at a dose of 8 mg/m2. Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ-glutamyltranspeptidase values were noted.",
keywords = "Canine, Carboplatin, Chemotherapy, Comparative oncology, Oncology, Rosiglitazone, Toxicity",
author = "{Allstadt Frazier}, S. and Mckemie, {D. S.} and Guerrero, {T. A.} and H. Lachapelle and Skorupski, {Katherine A} and Kass, {Philip H} and Rodriguez, {C. O.}",
year = "2014",
month = "3",
doi = "10.1111/j.1476-5829.2012.00322.x",
language = "English (US)",
volume = "12",
pages = "1--9",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs

AU - Allstadt Frazier, S.

AU - Mckemie, D. S.

AU - Guerrero, T. A.

AU - Lachapelle, H.

AU - Skorupski, Katherine A

AU - Kass, Philip H

AU - Rodriguez, C. O.

PY - 2014/3

Y1 - 2014/3

N2 - Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m2 to seven dogs. Carboplatin was administered at 240-300 mg/m2 in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose-limiting toxicity was hepatic at a dose of 8 mg/m2. Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ-glutamyltranspeptidase values were noted.

AB - Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m2 to seven dogs. Carboplatin was administered at 240-300 mg/m2 in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose-limiting toxicity was hepatic at a dose of 8 mg/m2. Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ-glutamyltranspeptidase values were noted.

KW - Canine

KW - Carboplatin

KW - Chemotherapy

KW - Comparative oncology

KW - Oncology

KW - Rosiglitazone

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84892975081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892975081&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5829.2012.00322.x

DO - 10.1111/j.1476-5829.2012.00322.x

M3 - Article

C2 - 22364238

AN - SCOPUS:84892975081

VL - 12

SP - 1

EP - 9

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 1

ER -